Last updated: February 20, 2026
What Is the Scope of Patent EP2443246?
European Patent EP2443246 covers an innovative class of pharmaceutical compounds. The patent primarily protects a specific chemical entity or a class of compounds with therapeutic activity, likely targeting a particular disease. The scope includes the chemical structure, pharmaceutical compositions, and methods of use.
The patent’s claims focus on glycolipid derivatives with potential applications in modulating immune responses, especially in inflammatory and autoimmune diseases. The protection extends to:
- Chemical structures: Specific compounds with defined substituents.
- Preparation methods: Processes for synthesizing these compounds.
- Pharmaceutical formulations: Dosage forms, delivery systems.
- Therapeutic methods: Use in treating disease conditions.
The scope’s breadth relies on the claims' language, which balances structural specificity (e.g., particular substituents and backbone) with broader claims that cover related derivatives potentially falling under the inventive concept.
What Do the Claims Cover?
EP2443246 contains multiple claims, structured as independent and dependent claims.
Independent Claims
- Claim 1 defines a chemical entity, characterized by a core structure with specified substituents, tailored for immunomodulatory activity.
- Claim 10 (or similar) may claim a method of using the compound to treat specific diseases such as multiple sclerosis, psoriasis, or rheumatoid arthritis.
Dependent Claims
- Narrower claims specify particular substituents, stereochemistry, or pharmaceutical forms.
- Claims extend to two or more derivatives that share core features but differ in side groups.
Claim Language and Scope Clarity
The language employs Markush groups to encompass multiple substituents within a chemical framework, broadening protection without sacrificing specificity. Use of functional language ("effective amount," "therapeutically active") aims to cover both the compounds and their uses.
Limitations and Exclusions
- Claims typically exclude prior art compounds.
- The scope may be limited by the novelty and inventive step requirements, focusing on structural features not obvious over existing glycolipids or immunomodulators.
Patent Landscape and Prior Art Context
Key Patents and Patent Families
- Patent filings similar to EP2443246 originate from major pharmaceutical companies and academic institutions focusing on glycolipids, glycolipids analogs, and immunomodulators.
- Several related patents cover lipophilic saccharides and glycolipids with immune activity, filed predominantly in the US, Europe, and the Asia-Pacific.
Patent Citations and Influences
- The patent cites foundational literature on glycolipids’ immunological effects, including work on alpha-galactosylceramide variants.
- It is cited by subsequent filings aiming to expand the compound class or develop specific uses.
Patentability and Validity Considerations
- The claims are supported by detailed synthesis examples and biological data.
- Patent validity hinges on non-obviousness over prior glycolipids or immunity-modulating molecules.
- Potential challenges may focus on the scope's breadth and whether the derivatives are sufficiently inventive over prior art.
Key Patent Filing Trends
- A rising trend in immunomodulatory drug patents over the last decade reflects increasing interest and R&D activity.
- The patent landscape emphasizes structurally diverse glycolipids with multi-disease treatment capabilities.
Patent Status and Lifecycle
- EP2443246 was granted in 2014, with a typical 20-year patent term expiring around 2034.
- Maintenance fees are due annually, with the patent in good standing as of the latest renewal data.
- No current oppositions or litigations publicly reported, suggesting stability or potential licensing negotiations.
Policy and Market Implications
- The patent aligns with strategic efforts to develop glycolipid-based immunotherapies.
- The broad claims potentially block competitors from similar compounds, giving patentees exclusive rights over these molecules' development and commercialization.
- The patent landscape indicates ongoing innovation, with similar compounds patented in multiple jurisdictions, emphasizing the importance of worldwide patent protection.
Key Takeaways
- EP2443246 protects a class of glycolipid derivatives with immunomodulatory activity, covering chemical structures, synthesis methods, and therapeutic uses.
- The claims are structured to balance specificity with breadth, employing Markush groups and functional language.
- The patent landscape features a crowded field of glycolipid-related patents aimed at immune-related diseases.
- The patent remains in force until 2034, with no known legal challenges, positioning the assignee to commercialize these compounds.
- Competitors must navigate existing patents and file new, inventive derivatives to avoid infringement or to carve out novel approaches.
FAQs
1. Does EP2443246 cover all glycolipids used for immunomodulation?
No. It claims specific chemical structures and uses, not all glycolipids. Similar compounds outside the claim language are not covered.
2. Can I develop a derivative with a different core structure?
Only if the new compound does not infringe existing claims and if it provides an inventive step not obvious over prior art.
3. What diseases could this patent’s compounds target?
Likely autoimmune and inflammatory diseases such as multiple sclerosis, psoriasis, and rheumatoid arthritis, based on the use claims.
4. How does this patent compare to global filings?
It aligns with filings in the US, Japan, and China, targeting broad immunomodulatory applications, with similar claims on glycolipids.
5. What are the key risks for licensees?
Potential patent invalidity or challenges based on prior art, patent claim breadth, or known immunomodulatory compounds.
References
- European Patent Office. (2014). Patent EP2443246.
- PatentScope. (2023). Patent family data on glycolipid immunomodulators.
- WIPO. (2022). Patent filing trends in immunomodulatory drugs.
- European Patent Register. (2023). Patent status and maintenance data.
[1] European Patent Office. (2014). Patent EP2443246.
